NINLARO Drug Patent Profile

Which patents cover Ninlaro, and what generic alternatives are available?

Ninlaro is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-seven patent family members in forty-four countries.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this compound. Additional details are available on the ixazomib citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Ninlaro

Ninlaro was eligible for patent challenges on November 20, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 16, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NINLARO

International Patents:	187
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	48
Drug Prices:	Drug price information for NINLARO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NINLARO
What excipients (inactive ingredients) are in NINLARO?	NINLARO excipients list
DailyMed Link:	NINLARO at DailyMed

See drug prices for NINLARO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NINLARO

NDA:

208462

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NINLARO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rajshekhar Chakraborty, MD	Phase 1/Phase 2
Genentech, Inc.	Phase 1/Phase 2
Takeda	Phase 4

See all NINLARO clinical trials

Pharmacology for NINLARO

Drug Class	Proteasome Inhibitor
Mechanism of Action	Proteasome Inhibitors

Paragraph IV (Patent) Challenges for NINLARO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NINLARO	Capsules	ixazomib citrate	2.3 mg, 3 mg and 4 mg	208462	1	2019-11-20

US Patents and Regulatory Information for NINLARO

NINLARO is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015		RX	Yes	Yes			Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No			Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No			Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015		RX	Yes	No
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015		RX	Yes	Yes			Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015		RX	Yes	No			Y	Y

Expired US Patents for NINLARO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015

International Patents for NINLARO

When does loss-of-exclusivity occur for NINLARO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Georgia, Republic of

Hong Kong

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NINLARO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	067824	COMPUESTOS DE ACIDO BORONICO Y ESTER BORONICO INHIBIDORES DE LA PROTEASOMA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USOS DE LOS MISMOS PARA EL TRATAMIENTO DEL CANCER.
Australia	2007357338	Proteasome inhibitors
Brazil	PI0721905	INIBIDORES DE PROTEASSOMA
Canada	2695082	INHIBITEURS DE PROTEASOMES (PROTEASOME INHIBITORS)
Chile	2008002159	Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad.
China	101772507	Proteasome inhibitors
China	102961387	Proteasome inhibitor

Supplementary Protection Certificates for NINLARO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2178888	PA2017010	Lithuania		PRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR ESTERIAI, PAVYZDZIUI KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2178888	300871	Netherlands		PRODUCT NAME: IXAZOMIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN EN ESTERS DAARVAN, ZOALS IXAZOMIBCITRAAT; REGISTRATION NO/DATE: EU/1/16/1094 20161123
2178888	122017000025	Germany		PRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2178888	CA 2017 00014	Denmark		PRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123
2178888	C20170014 00227	Estonia		PRODUCT NAME: IKSASOMIIB;REG NO/DATE: EU/1/16/1094 23.11.2016
2178888	PA2017010,C2178888	Lithuania		PRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA IR ESTERIS, TOKS KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2178888	LUC00013	Luxembourg		PRODUCT NAME: IXAZOMIB ET SELS ET ESTERS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI, TEL QUE LE CITRATE D'IXAZOMIB; AUTHORISATION NUMBER AND DATE: EU/1/16/&1094 20161123

Last updated: July 19, 2026

NINLARO market dynamics and financial trajectory: exclusivity, competitive pressure, and revenue outlook

Ninlaro (ixazomib) is an oral proteasome inhibitor for multiple myeloma that has moved from launch-era growth into a more mature, competition-driven phase. Financial trajectory is shaped by (1) patent and exclusivity expiries that govern generic and biosimilar-like substitution risk, (2) expanding standard-of-care uptake of newer regimens, and (3) distributor and payer dynamics for oral myeloma therapy. The net effect is pressure on price and prescription growth as competitors widen use cases and as clinicians migrate to combination backbones that include newer agents.

---

What is Ninlaro’s commercial positioning in multiple myeloma and why does it matter for revenue?

Ninlaro is positioned as an oral triplet backbone component in multiple myeloma, historically used with lenalidomide and dexamethasone. Its market role has typically depended on:

• Convenience economics: oral dosing reduces infusion-center utilization versus IV proteasome inhibitors, which can improve patient adherence and reduce site-of-care costs.
• Treatment sequencing: proteasome inhibitors are used across lines of therapy. Ninlaro’s share depends on whether clinicians prefer oral ixazomib over alternatives in later-line relapsed/refractory settings.
• Payer formulary placement: oral myeloma regimens often face step edits tied to guideline pathways, prior authorization, and real-world response thresholds.
• Combination performance: uptake correlates with regimen-level outcomes and tolerability versus competing oral and injectable backbones.

Revenue drivers that typically show up in financial statements

• Prescription volumes for 2.3 mg, 3 mg, and 4 mg capsules (dose intensity and persistence).
• Trade inventory movements with wholesalers, especially during post-guideline shifts or after payer policy changes.
• Net price effects from rebates, discounts, and contract re-negoitiations tied to competitor launches.

---

How have Ninlaro’s sales trended since launch and what do the trends signal about market maturity?

Observed market maturity pattern

• Early period: faster adoption driven by clinical credibility and regimen fit.
• Mid period: growth slows as competitors enter with improved outcomes, and as payer restrictions tighten around preferred triplets.
• Current period: revenue becomes more dependent on maintenance use, line-of-therapy inertia, and negotiated pricing rather than broad new patient starts.

Signals for financial trajectory

• Volume growth that outpaces price cuts usually indicates strong regimen stickiness.
• Price compression without offsetting volume suggests formulary substitution and competitor advantage in the regimen backbone.
• Declines with stable volume can indicate adverse contract terms and higher net-to-gross discounting.

Because Ninlaro’s commercial base is mature, small shifts in formulary access can produce outsized financial changes compared with launch dynamics.

---

What patents protect Ninlaro and what does that mean for generic and biosimilar entry risk?

Ninlaro exclusivity risk is governed by a combination of Orange Book-listed patents and legal exclusivity timelines. For small-molecule drugs like ixazomib, the primary threat is generic substitution after patent expiry or successful Paragraph IV litigation.

Key practical risk concepts

• Patent estate breadth: multiple patent families across composition, formulation, and method-of-use can extend protection even after the “core” molecule patents expire.
• Orange Book scope: strength depends on whether patents are listed for the specific strength and dosage form.
• Legal pathway control: generic entry timing depends on whether ANDA filers can design around unexpired claims and whether they win/settle Paragraph IV cases.

Commercial implication

• When the patent estate is thick and includes formulation and method-of-use claims, generic entry can be delayed or constrained to narrower carve-outs.
• When the estate is thin or claims are weak, the market can shift quickly after first expiry dates, triggering price erosion.

---

When does Ninlaro lose exclusivity and when could generic launches occur?

Exclusivity and generic launch timing are driven by the last-to-expire eligible patent relevant to the specific product(s) listed in FDA’s Orange Book.

In ixazomib’s case, generic entry is a function of:

• the latest patent expiry date in the Orange Book listing for capsules by strength; and
• any additional litigation settlements that set “carve-out” launch windows or specified effective dates; and
• whether ANDA applicants secure 180-day exclusivity triggered by first-filer status.

Financial trajectory implication

• Revenue typically holds relatively steady up to the final years of the patent wall.
• The year of launch risk often shows accelerated discounting and patient routing moves by manufacturers and payers to pre-position for generic substitution.

(Full, claim-specific expiry mapping is not provided here because it requires product-strength-specific Orange Book patent tables and litigation docket alignment.)

---

What Paragraph IV challenges exist for Ninlaro and how do they affect market share?

Paragraph IV litigation affects revenue in two ways:

1. Potential early launch: If the court invalidates key claims or finds non-infringement, generics can launch before the latest scheduled expiry.
2. Settlement-based timing: If parties settle, the launch can be delayed in exchange for a payment or licensing terms.

How this shows up commercially

• Net sales may drop before the formal generic launch if wholesalers cut orders due to anticipated substitution.
• Price pressure can intensify during the settlement window because payers pre-contract for generic or adopt preferred alternatives.

---

What formulations are protected for Ninlaro and how do formulation patents shape generic design?

For small molecules, formulation patents can cover:

• capsule compositions and excipient systems,
• stability and dissolution specifications,
• manufacturing methods affecting bioavailability (where claim language ties to performance parameters).

Generic design impact

• If formulation claims are broad and tied to the delivered exposure profile, ANDA applicants may be forced into design-around strategies that take time and increase risk.
• If formulation patents are narrow, generics can replicate the composition with minimal clinical bridging, compressing launch time.

---

What method-of-use patents protect Ninlaro’s clinical indications and how do they constrain generic labeling?

Method-of-use (and treatment regimen) patents can delay effective substitution because even if a generic product is approved, it may be restricted to non-patented dosing regimens.

Commercial consequences

• Payers may still be able to use an approved generic for non-patented indications, but clinician behavior and reimbursement may lag.
• Brand may preserve share if its covered regimen is the most commonly prescribed in the real-world setting.

---

How does Ninlaro compare with Velcade (bortezomib) and Kyprolis (carfilzomib) on market dynamics and payer uptake?

Key commercial comparison axes

• Route of administration: Ninlaro’s oral format tends to support patient convenience narratives and can reduce facility costs versus IV proteasome inhibitors.
• Adverse event profile: dosing schedules and neuropathy or cardiopulmonary tolerability affect line-of-therapy selection.
• Combination backbones: how Ninlaro integrates into lenalidomide-based regimens influences uptake.

Market share dynamics

• If clinicians view newer IV or carfilzomib-based regimens as superior for certain subpopulations, Ninlaro share can stagnate even if it remains clinically credible.
• If payer policies favor oral regimens for administrative simplicity and adherence outcomes, Ninlaro can sustain better-than-average volume.

---

Which newer myeloma therapies are pulling share from Ninlaro and what does that do to forecasted sales?

In relapsed/refractory multiple myeloma, share can be pulled by:

• newer proteasome inhibitor regimens,
• next-generation immunomodulatory agents,
• antibody-drug conjugates and T-cell redirecting therapies,
• and altered sequencing driven by emerging survival data and convenience advantages.

Forecast impact

• If clinicians shift triplet backbones from ixazomib to alternative compounds, Ninlaro volumes decline first.
• If Ninlaro retains access but faces price pressure due to payer preference for competing oral therapies, revenue can flatten despite stable prescriptions.

---

What is the Orange Book status of Ninlaro and how does it translate into commercial risk?

Orange Book status translates into commercial risk via:

• number of listed patents tied to each dosage strength,
• breadth of claims (composition, formulation, use),
• and whether those claims have survived prior litigation challenges.

Risk interpretation for business planning

• A dense, multi-family Orange Book listing generally reduces probability of rapid full-generic substitution.
• A sparse listing with early expiries increases risk of accelerated revenue erosion.

(Orange Book listing tables and patent identifiers are not included here because the prompt does not provide access to the specific Orange Book record for ixazomib capsules.)

---

How do pricing, rebates, and contracting affect Ninlaro’s net sales more than gross demand?

For branded oral oncology therapies, net sales are often more sensitive to:

• payer formulary tier placement (preferred vs non-preferred),
• rebate rates and utilization caps,
• contracting with large integrated delivery networks,
• and pharmacy benefit manager (PBM) incentives.

Typical financial pattern

• If demand is resilient, net sales can still decline due to contract renegotiations.
• If demand softens, the company often responds with additional contracting actions that can accelerate net-to-gross deterioration.

For forecasting, volume elasticity and net pricing trend should be treated as separate drivers.

---

What litigation, settlements, or exclusivity events could change Ninlaro’s revenue path?

Revenue inflection points usually come from:

• court rulings that invalidate or narrow specific Orange Book patents;
• entry of first-filer ANDA products that trigger 180-day exclusivity;
• settlement agreements that fix launch timing;
• and regulatory label changes that affect competitive positioning.

Commercial mechanism

• Any credible launch window can move wholesalers and payer contracting behavior, compressing brand share even before the first generic unit ships.

---

What manufacturing and IP barriers would slow generic entry for Ninlaro?

Generic speed is constrained by:

• formulation equivalence and stability,
• acceptable bioequivalence and dissolution targets,
• and regulatory chemistry, manufacturing, and controls (CMC) readiness.

If the brand has multiple patent-protected manufacturing or formulation variants, ANDA design-around can increase development timelines and litigation uncertainty, slowing launch and reducing the probability of immediate share loss.

---

Key Takeaways

• Ninlaro’s market dynamics reflect a mature proteasome-inhibitor niche where revenue is driven by regimen fit, oral convenience advantages, and formulary access.
• The financial trajectory is primarily shaped by patent estate strength and Orange Book coverage, which determines generic launch feasibility and timing.
• Competitive pressure comes from newer myeloma treatment backbones that can alter clinician sequencing and payer preference, shifting volumes away even when absolute clinical need remains.
• Net sales sensitivity to contracting and rebates often dominates near-term revenue outcomes in mature oncology brands.
• Litigation and settlement events function as revenue inflection points by changing anticipated substitution timelines.

---

FAQs

1) Does Ninlaro face generic competition even if its core molecule patents expire later?
Yes. Generic launch risk depends on the last-to-expire relevant Orange Book patents, including formulation and method-of-use claims tied to specific strengths.

2) How do oral proteasome inhibitors compete against IV regimens in payer formularies?
Payer preference often hinges on total allowed costs, reimbursement handling, and prior authorization barriers that reward preferred oral regimens when clinical outcomes are comparable.

3) What happens to brand share in the months before generic launch?
Wholesalers and payers often adjust inventories and contracting ahead of expected substitution, which can create early share loss even before first generic shipments.

4) Can method-of-use patents limit generic switching without stopping ANDA approval?
Yes. Generics can be approved for labeling carve-outs that exclude patented regimens, delaying therapeutic substitution for the most common treatment pathway.

5) What financial metrics best indicate Ninlaro’s near-term trajectory?
Prescription volumes by strength, unit persistence, net price and net-to-gross trends, and wholesaler inventory movements versus expected demand.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database).
2. FDA. ANDA Paragraph IV Certification and Litigation Overview. (FDA/ANDA guidance and related resources).
3. U.S. District Court and Federal Circuit dockets. Biopharmaceutical patent litigation records related to ixazomib and Ninlaro (docket-specific records).